FDA-approved
Hormones & metabolism
Lixisenatide
Evidence
FDA approved
Class
GLP-1 receptor agonist
KEY TAKEAWAY
Lixisenatide is a short-acting GLP-1 receptor agonist based on exendin-4. It was sold as Adlyxin. The FDA approved lixisenatide (Adlyxin) in 2016. The manufacturer discontinued Adlyxin in the United States in 2023, and a combination with insulin glargine (Soliqua) remains available.
Written by the Veylo editorial team · Updated
November 2026
What it is
GLP-1 receptor agonist
Approved for
Type 2 diabetes
Key fact
The FDA approved lixisenatide (Adlyxin) in 2016. The manufacturer discontinued Adlyxin in the United States in 2023, and a combination with insulin glargine (Soliqua) remains available.
Route
Daily subcutaneous injection
Evidence strength
FDA approved
Lixisenatide is a short-acting GLP-1 receptor agonist based on exendin-4. It was sold as Adlyxin.
It activates GLP-1 receptors, which raises insulin release when blood sugar is high and slows stomach emptying.
The FDA approved lixisenatide (Adlyxin) in 2016. The manufacturer discontinued Adlyxin in the United States in 2023, and a combination with insulin glargine (Soliqua) remains available.
Type 2 diabetes.
Nausea, vomiting and diarrhea are common. Pancreatitis is a rare serious risk.
U.S. FDA prescribing information for Lixisenatide. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.